A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

NCT07669051 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: ivonescimab plus EGFR-TKI.

Sponsor

Shandong Cancer Hospital and Institute